Have a personal or library account? Click to login
Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania Cover

Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania

Journal of Cardiovascular Emergencies
Volume 5 (2019): Issue 4 (December 2019)
By: László Lorenzovici,  Andrea Székely,  Szabolcs Farkas-Ráduly,  Ciprian Jitaru and  Marcell Csanádi  
Open Access
|Jan 2020

References

  1. 1. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21:365-371. doi: 10.1016/j.carpath.2011.11.007.10.1016/j.carpath.2011.11.00722227365
    Open DOISearch in Google ScholarBack to article
  2. 2. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime Risk for Developing Congestive Heart Failure. Circulation. 2002;106:3068-3072. doi: 10.1161/01.CIR.0000039105.49749.6F.10.1161/01.CIR.0000039105.49749.6
    Open DOISearch in Google ScholarBack to article
  3. 3. Bredy C, Ministeri M, Kempny A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome. Eur Heart J Qual Care Clin Outcomes. 2018;4:51-58. doi: 10.1093/ehjqcco/qcx031.10.1093/ehjqcco/qcx03128950356
    Open DOISearch in Google ScholarBack to article
  4. 4. Chioncel O, Tatu-Chitoiu G, Christodorescu R, et al. Characteristics of patients with heart failure from Romania enrolled in - ESC-HF Long-Term (ESC-HF-LT) Registry. Romanian Journal of Cardiology. 2015;25:413-420.
    Search in Google ScholarBack to article
  5. 5. Sinescu C, Axente L. Heart failure – concepts and significance. Birth of a prognostic model. J Med Life. 2010;3:421-429.
    Search in Google ScholarBack to article
  6. 6. Pop D, Penciu OM, Sitar-Taut AV, Zdrenghea DT. Comparative heart failure profile over a 3-year period in a Romanian general hospital. Clin Interv Aging. 2013;8:999-1005. doi: 10.2147/CIA.S46760.10.2147/CIA.S46760373387323930074
    Search in Google ScholarBack to article
  7. 7. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J. 2013;165:575-82.e3. doi: 10.1016/j.ahj.2013.01.017.10.1016/j.ahj.2013.01.01723537975
    Open DOISearch in Google ScholarBack to article
  8. 8. Cleland JGF, Zhang J, Pellicori P, et al. Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure. JAMA Cardiol. 2016;1:539-547. doi: 10.1001/jamacardio.2016.1161.10.1001/jamacardio.2016.116127439011
    Search in Google ScholarBack to article
  9. 9. Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58:1241-1251. doi: 10.1016/j.jacc.2011.04.040.10.1016/j.jacc.2011.04.04021903058
    Open DOISearch in Google ScholarBack to article
  10. 10. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872-1880. doi: 10.1093/eurheartj/ehq158.10.1093/eurheartj/ehq15820570952
    Search in Google ScholarBack to article
  11. 11. Comín-Colet J, Enjuanes C, González G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15:1164-1172. doi: 10.1093/eurjhf/hft083.10.1093/eurjhf/hft083378214623703106
    Open DOISearch in Google ScholarBack to article
  12. 12. Dalal J, Katekhaye V, Jain R. Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: A meta-analysis. Indian Heart J. 2017;69:736-741. doi: 10.1016/j.ihj.2017.10.009.10.1016/j.ihj.2017.10.009571730029174251
    Open DOISearch in Google ScholarBack to article
  13. 13. Anker SD, Comín-Colet J, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361:2436-2448. doi: 10.1056/NEJMoa0908355.10.1056/NEJMoa090835519920054
    Open DOISearch in Google ScholarBack to article
  14. 14. Ponikowski P, van Veldhuisen DJ, Comín-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657-668. doi: 10.1093/eurheartj/ehu385.10.1093/eurheartj/ehu385435935925176939
    Open DOISearch in Google ScholarBack to article
  15. 15. Hotărârea de Guvern nr. Nr. 140/2018 din 21 martie 2018 publicată în Monitorul Oficial al României Partea I, nr. 270 din 27 martie 2018. Available at: http://www.casan.ro/casalba/media/postFiles/HG%20140-CONTRACT%20CADRU%202018-2019.pdf
    Search in Google ScholarBack to article
  16. 16. Ordinul ministrului sănătății și al președintelui Casei Naționale de Asigurări de Sănătate nr. 397/836/2018 privind aprobarea Normelor metodologice de aplicare în anul 2018 a Hotărârii Guvernului nr. 140/2018 pentru aprobarea pachetelor de servicii și a Contractului-cadru care reglementează condițiile acordării asistenței medicale, a medicamentelor și a dispozitivelor medicale în cadrul sistemului de asigurări sociale de sănătate pentru anii 2018-2019. Available at: http://www.cnas.ro/casgorj/media/postFiles/Ordin%20397-836_2018%20(actualizat%20cu%20Ordin%20MS-CNAS%20910-1161_2018).pdf
    Search in Google ScholarBack to article
  17. 17. Theidel U, Väätäinen S, Martikainen J, Soini E, Hardt T, Doehner W. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC heart failure. 2017;4:274-281. doi: 10.1002/ehf2.12179.10.1002/ehf2.12179554273128772041
    Open DOISearch in Google ScholarBack to article
  18. 18. Bourguignon S, Faller M, Champs F-O, et al. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Fail. 2019;6:559-569. doi: 10.1002/ehf2.12432.10.1002/ehf2.12432648771731021531
    Open DOISearch in Google ScholarBack to article
  19. 19. Ressl S, Walter E, Bauer M. Budget-Impact-Analysis Of Iron Treatment Using Intravenous Ferric Carboxymaltose In Patients With Chronic Heart Failure And Iron Deficiency In Austria. Value Health. 2015;18:A384. doi: 10.1016/j.jval.2015.09.831.10.1016/j.jval.2015.09.831
    Open DOISearch in Google ScholarBack to article
  20. 20. Walter E, Bauer M, Ressl S. Cost-Effectiveness Of Ferric Carboxymaltose In Patients With Iron Deficiency And Chronic Heart Failure In Austria. Value Health. 2015;18:A392. doi: 10.1016/j.jval.2015.09.876.10.1016/j.jval.2015.09.876
    Open DOISearch in Google ScholarBack to article
  21. 21. Gutzwiller FS, Schwenkglenks M, Blank PR, et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur J Heart Fail. 2012;14:782-790. doi: 10.1093/eurjhf/hfs083.10.1093/eurjhf/hfs083338054622689292
    Open DOISearch in Google ScholarBack to article
  22. 22. Comín-Colet J, Rubio-Rodríguez D, Rubio-Terrés C, et al. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Rev Esp Cardiol (Engl Ed). 2015;68:846-851. doi: 10.1016/j.rec.2014.10.010.10.1016/j.rec.2014.10.01025649970
    Open DOISearch in Google ScholarBack to article
  23. 23. Hofmarcher T, Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J Med Econ. 2015;18:492-501. doi: 10.3111/13696998.2015.1029491.10.3111/13696998.2015.102949125766863
    Open DOISearch in Google ScholarBack to article
  24. 24. Mylonas C, Kourlaba G, Berberian K, Maniadakis N. Economic Evaluation Of Ferric Carboxymaltose In Patients With Chronic Heart Failure And Iron Deficiency: An Analysis For Greece Based On Fair-Hf Trial. Value Health. 2014;17:A486. doi: 10.1016/j.jval.2014.08.1424.10.1016/j.jval.2014.08.142427201432
    Open DOISearch in Google ScholarBack to article
  25. 25. Lim EA, Sohn HS, Lee H, Choi SE. Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea. Cost effectiveness and resource allocation: C/E. 2014;12:19. doi: 10.1186/1478-7547-12-19.10.1186/1478-7547-12-19416657425278814
    Open DOISearch in Google ScholarBack to article
  26. 26. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1002/ejhf.592.10.1002/ejhf.59227207191
    Open DOISearch in Google ScholarBack to article
DOI: https://doi.org/10.2478/jce-2019-0018 | Journal eISSN: 2457-5518 | Journal ISSN: 2457-550X
Journal RSS Feed
Language: English
Page range: 131 - 139
Submitted on: Sep 17, 2019
|
Accepted on: Dec 13, 2019
|
Published on: Jan 21, 2020
Published by: Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
heart failure,
iron deficiency,
treatment cost,
budget impact,
ferric carboxymaltose,
Romania
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Cardiology,
Emergency medicine and intensive-care medicine,
Radiology

© 2020 László Lorenzovici, Andrea Székely, Szabolcs Farkas-Ráduly, Ciprian Jitaru, Marcell Csanádi, published by Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 5 (2019): Issue 4 (December 2019)Next article